JP2006511596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511596A5 JP2006511596A5 JP2005501006A JP2005501006A JP2006511596A5 JP 2006511596 A5 JP2006511596 A5 JP 2006511596A5 JP 2005501006 A JP2005501006 A JP 2005501006A JP 2005501006 A JP2005501006 A JP 2005501006A JP 2006511596 A5 JP2006511596 A5 JP 2006511596A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- ethyl
- carboxamide
- indole
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 208000006673 asthma Diseases 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 17
- 206010006451 bronchitis Diseases 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 201000009267 bronchiectasis Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 230000000155 isotopic effect Effects 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- -1 hydroxy, methyl Chemical group 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000010659 intrinsic asthma Diseases 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000024711 extrinsic asthma Diseases 0.000 claims 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- JIIXGDGLWIDEHT-CLYVBNDRSA-N 5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-n-[(2-methoxyphenyl)methyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C1=CC2=CC(C[C@@H](C)NC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=C2N1 JIIXGDGLWIDEHT-CLYVBNDRSA-N 0.000 claims 1
- JHRNSGOBXJUMPH-WRHNGFHOSA-N 5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-n-[(3-methoxyphenyl)methyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC(CNC(=O)C=2NC3=CC=C(C[C@@H](C)NC[C@H](O)C=4C=C(CO)C(O)=CC=4)C=C3C=2)=C1 JHRNSGOBXJUMPH-WRHNGFHOSA-N 0.000 claims 1
- FDAKLYKEIOPOKK-XBBWARJSSA-N 5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-n-[2-(3-methoxyphenyl)ethyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC(CCNC(=O)C=2NC3=CC=C(C[C@@H](C)NC[C@H](O)C=4C=C(CO)C(O)=CC=4)C=C3C=2)=C1 FDAKLYKEIOPOKK-XBBWARJSSA-N 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010011416 Croup infectious Diseases 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000036428 airway hyperreactivity Effects 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 201000010549 croup Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- WTBGOYCHEVMMHF-CLYVBNDRSA-N n-[(2,6-dimethoxyphenyl)methyl]-5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC(OC)=C1CNC(=O)C1=CC2=CC(C[C@@H](C)NC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=C2N1 WTBGOYCHEVMMHF-CLYVBNDRSA-N 0.000 claims 1
- 208000007892 occupational asthma Diseases 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020292513 EP1407769A1 (en) | 2002-10-11 | 2002-10-11 | Indole derivatives as beta-2 agonists |
| EP03290069A EP1440966A1 (en) | 2003-01-10 | 2003-01-10 | Indole derivatives useful for the treatment of diseases |
| PCT/IB2003/004441 WO2004032921A1 (en) | 2002-10-11 | 2003-10-06 | Indole derivatives as beta-2 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006511596A JP2006511596A (ja) | 2006-04-06 |
| JP2006511596A5 true JP2006511596A5 (https=) | 2006-06-22 |
| JP4490911B2 JP4490911B2 (ja) | 2010-06-30 |
Family
ID=32095049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501006A Expired - Fee Related JP4490911B2 (ja) | 2002-10-11 | 2003-10-06 | β−２アゴニストとしてのインドール誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1556034B1 (https=) |
| JP (1) | JP4490911B2 (https=) |
| KR (1) | KR20050047552A (https=) |
| AP (1) | AP2005003283A0 (https=) |
| AR (1) | AR041566A1 (https=) |
| AT (1) | ATE392206T1 (https=) |
| AU (1) | AU2003269316A1 (https=) |
| BR (1) | BR0315234A (https=) |
| CA (1) | CA2499314C (https=) |
| CO (1) | CO5550421A2 (https=) |
| DE (1) | DE60320439T2 (https=) |
| EA (1) | EA200500618A1 (https=) |
| EC (1) | ECSP055780A (https=) |
| ES (1) | ES2302938T3 (https=) |
| IS (1) | IS7751A (https=) |
| MA (1) | MA27452A1 (https=) |
| MX (1) | MXPA05003866A (https=) |
| NO (1) | NO20051406L (https=) |
| OA (1) | OA12938A (https=) |
| PA (1) | PA8586001A1 (https=) |
| PE (1) | PE20040775A1 (https=) |
| PL (1) | PL376396A1 (https=) |
| TW (1) | TW200424171A (https=) |
| UY (1) | UY28013A1 (https=) |
| WO (1) | WO2004032921A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| EP1460064A1 (en) * | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2005092841A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| BRPI0614290A2 (pt) | 2005-08-08 | 2011-03-22 | Argenta Discovery Ltd | derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos |
| RU2421464C2 (ru) | 2005-10-21 | 2011-06-20 | Новартис Аг | Человеческие антитела к il-13 и их терапевтическое применение |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| RS20080411A (sr) | 2006-03-20 | 2009-07-15 | Pfizer Limited, | Derivati amina |
| EP2322525B1 (en) | 2006-04-21 | 2013-09-18 | Novartis AG | Purine derivatives for use as adenosin A2A receptor agonists |
| BRPI0714463A2 (pt) | 2006-07-19 | 2013-04-02 | Astrazeneca Ab | compostos de espiropiperidina tricÍclicos, sua sÍntese e seus usos como moduladores de atividade receptora de quimiocina |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| AU2007336054A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
| PL2104535T3 (pl) | 2007-01-10 | 2011-05-31 | Irm Llc | Związki i kompozycje jako inhibitory proteazy aktywujące kanały |
| CN101646437A (zh) | 2007-02-09 | 2010-02-10 | Irm责任有限公司 | 作为通道活化蛋白酶抑制剂的化合物和组合物 |
| DE602008005140D1 (de) | 2007-05-07 | 2011-04-07 | Novartis Ag | Organische verbindungen |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| MX2010007604A (es) | 2008-01-11 | 2010-08-02 | Novartis Ag | Pirimidinas como inhibidores de cinasa. |
| EA017627B1 (ru) | 2008-05-13 | 2013-01-30 | Астразенека Аб | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора |
| EP2297106B1 (en) | 2008-05-27 | 2014-07-16 | AstraZeneca AB | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
| JP2011522860A (ja) | 2008-06-10 | 2011-08-04 | ノバルティス アーゲー | 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体 |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
| ES2442343T3 (es) | 2008-12-30 | 2014-02-11 | Pulmagen Therapeutics (Inflammation) Limited | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| JP5801997B2 (ja) | 2009-07-07 | 2015-10-28 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器 |
| MX2012004792A (es) | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| HRP20151317T1 (hr) | 2011-06-10 | 2016-01-01 | Chiesi Farmaceutici S.P.A. | Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| NZ708738A (en) | 2012-12-06 | 2019-02-22 | Chiesi Farm Spa | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2014086927A1 (en) | 2012-12-06 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| AR099336A1 (es) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| PE20220346A1 (es) | 2019-08-28 | 2022-03-14 | Novartis Ag | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades |
| CN116033893A (zh) | 2020-06-26 | 2023-04-28 | 迈兰制药英国有限公司 | 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9406823A (pt) * | 1993-06-14 | 1996-03-26 | Pfizer | Aminas secundárias e agentes anti-diabéticos e antiobesidade |
| EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| EP0822185A1 (en) * | 1996-07-31 | 1998-02-04 | Pfizer Inc. | B-3-adrenergic agonists as antidiabetic and antiobesity agents |
-
2003
- 2003-10-06 EP EP03751095A patent/EP1556034B1/en not_active Expired - Lifetime
- 2003-10-06 OA OA1200500099A patent/OA12938A/en unknown
- 2003-10-06 BR BR0315234-0A patent/BR0315234A/pt not_active IP Right Cessation
- 2003-10-06 JP JP2005501006A patent/JP4490911B2/ja not_active Expired - Fee Related
- 2003-10-06 CA CA2499314A patent/CA2499314C/en not_active Expired - Fee Related
- 2003-10-06 AU AU2003269316A patent/AU2003269316A1/en not_active Abandoned
- 2003-10-06 MX MXPA05003866A patent/MXPA05003866A/es not_active Application Discontinuation
- 2003-10-06 PL PL03376396A patent/PL376396A1/xx unknown
- 2003-10-06 DE DE60320439T patent/DE60320439T2/de not_active Expired - Lifetime
- 2003-10-06 KR KR1020057006090A patent/KR20050047552A/ko not_active Ceased
- 2003-10-06 WO PCT/IB2003/004441 patent/WO2004032921A1/en not_active Ceased
- 2003-10-06 ES ES03751095T patent/ES2302938T3/es not_active Expired - Lifetime
- 2003-10-06 AP AP2005003283A patent/AP2005003283A0/xx unknown
- 2003-10-06 AT AT03751095T patent/ATE392206T1/de not_active IP Right Cessation
- 2003-10-06 EA EA200500618A patent/EA200500618A1/ru unknown
- 2003-10-09 AR ARP030103677A patent/AR041566A1/es unknown
- 2003-10-09 PE PE2003001024A patent/PE20040775A1/es not_active Application Discontinuation
- 2003-10-09 TW TW092128121A patent/TW200424171A/zh unknown
- 2003-10-10 PA PA20038586001A patent/PA8586001A1/es unknown
- 2003-10-10 UY UY28013A patent/UY28013A1/es not_active Application Discontinuation
-
2005
- 2005-03-17 IS IS7751A patent/IS7751A/is unknown
- 2005-03-17 NO NO20051406A patent/NO20051406L/no unknown
- 2005-04-08 CO CO05032119A patent/CO5550421A2/es not_active Application Discontinuation
- 2005-04-11 MA MA28210A patent/MA27452A1/fr unknown
- 2005-05-05 EC EC2005005780A patent/ECSP055780A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511596A5 (https=) | ||
| JP2006526613A5 (https=) | ||
| CA2499314A1 (en) | Indole derivatives as beta-2 agonists | |
| JP2009530364A5 (https=) | ||
| CA2643097A1 (en) | Amine derivatives | |
| AU738134B2 (en) | Amidocarboxylic acid derivatives | |
| JP5143557B2 (ja) | 可溶性アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬 | |
| JP4805824B2 (ja) | キャップ化ピラジノイルグアニジンナトリウムチャネルブロッカー | |
| US20100016274A1 (en) | Beta-lactam cannabinoid receptor modulators | |
| HRP20180116T1 (hr) | (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i | |
| CN1474818A (zh) | 含有稠合杂环化合物或其盐的糖尿病预防或治疗药 | |
| RU2009134512A (ru) | Гидрохлоридная соль 5-[3-(3-гидроксифенокси)азетедин-1-ил]-5-метил-2,2-дифенилгексанамида | |
| JP2005533058A (ja) | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート | |
| JP2009539882A (ja) | ベータアゴニスト活性を有するフェニル置換ピラジノイルグアニジンナトリウムチャネル遮断薬 | |
| US20080242649A1 (en) | New Combination 665 | |
| JP2011511835A5 (https=) | ||
| JP2003516314A (ja) | ライノウイルス感染症におけるｃｓａｉｄの使用 | |
| JP2014508720A5 (https=) | ||
| JP2004530648A (ja) | 炎症により促進される咳の治療のためのｐ３８阻害剤の使用 | |
| JP2016505582A5 (https=) | ||
| US20200101046A1 (en) | Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections | |
| CA2705729A1 (en) | Pyrazole derivatives as 5-lo inhibitors | |
| JP2015504874A5 (https=) | ||
| JP2007503458A (ja) | ベータ２アゴニストとしての（２−ヒドロキシ−２−（４−ヒドロキシ−３−ヒドロキシメチルフェニル）−エチルアミノ）−プロピル！フェニル誘導体 | |
| JP4564654B2 (ja) | Ｖｌａ−４アンタゴニスト |